GP180: A Drug Target and Potential Biomarker for Various Diseases

Target Name: CPD

NCBI ID: G1362

Content of Review Report on CPD Target / Biomarker

CPD

GP180: A Drug Target and Potential Biomarker for Various Diseases

CPD (GPI-180) is a drug target and a potential biomarker for various diseases, including cancer. CPD is a protein that is expressed in various tissues and cells in the body, including the brain, lungs, heart, and gastrointestinal tract. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a crucial role in cellular signaling.

GP180 is a specific subtype of GPCR that is characterized by its unique expression pattern and function. It is expressed in the brain and is involved in the regulation of various physiological processes, including pain perception, anxiety, and inflammation.

One of the key features of GP180 is its role in pain perception. GP180 is known to play a crucial role in the regulation of pain signals in the brain, and is involved in the production and release of endogenous opioids that can alleviate pain. Additionally, GP180 is also involved in the regulation of anxiety and stress, and is known to interact with other GPCRs, including GPR55 and GPR75, which are involved in anxiety and stress signaling.

Another potential function of GP180 is its role in inflammation. GP180 is involved in the regulation of inflammation in various tissues and organs, and is known to play a negative role in the development of inflammatory diseases, such as cancer.

In addition to its potential functions in pain perception and inflammation, GP180 is also a potential drug target. Several studies have identified potential small molecules that can interact with GP180 and modulate its function. These small molecules include compounds that can inhibit the activity of GP180, as well as compounds that can activate its activity.

One of the most promising potential drug targets for GP180 is the use of small molecules that can inhibit its activity in pain perception and inflammation. These small molecules include natural compounds, such as menthol, capsaicin, and niacin, as well as synthetic compounds, such as morphine, codeine, and fenfloxacin.

In conclusion, CPD (GP180) is a drug target and a potential biomarker for various diseases, including cancer. Its unique expression pattern and function make it an attractive target for small molecules that can modulate its activity. Further research is needed to fully understand the role of GP180 in pain perception, anxiety, and inflammation, as well as its potential as a drug target.

Protein Name: Carboxypeptidase D

The "CPD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets